Physician profile
Sablaa Ali
NPI 1548500333
$2,451.55
in general payments reported to CMS, 2019-2025
26 companies · $396 in 2025
The $396 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $345 · 2020: $241 · 2021: $951 · 2022: $306 · 2024: $213 · 2025: $396.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $609.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $609.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $878.19 | 2019-2025 | Ozempic |
| Amgen INC. | $361.99 | 2019-2025 | Tepezza |
| Dexcom, INC. | $124.50 | 2024-2025 | Dexcom G6 Transmitter |
| Ablative Solutions, INC. | $123.20 | 2021 | |
| Medtronic Minimed, INC. | $123.15 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $120.88 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $97.51 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $91.99 | 2019-2022 | |
| Tandem Diabetes Care, INC. | $77.51 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Corcept Therapeutics | $50.94 | 2021-2022 | |
| Daiichi Sankyo INC. | $46.69 | 2024 | Enhertu |
| Astellas Pharma US INC | $39.10 | 2019-2025 | Padcev |
| Angiodynamics, INC. | $34.86 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $33.73 | 2020-2021 | |
| Glaxosmithkline, LLC. | $32.36 | 2020 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Millicent US INC | $32.31 | 2025 | Intrarosa |
| Sanofi-Aventis U.S. LLC | $29.20 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $23.57 | 2021 | |
| Medtronic, INC. | $21.60 | 2024 | Minimed 780g |
| Cvrx, INC. | $20.41 | 2020 | |
| Elutia, INC. | $19.06 | 2021 | |
| Genentech USA, INC. | $15.48 | 2024 | Polivy, Phesgo, Tecentriq |
| Stemline Therapeutics INC. | $14.40 | 2024 | Orserdu |
| Merck Sharp & Dohme LLC | $13.54 | 2022 | |
| Becton, Dickinson and Company | $12.72 | 2019 | |
| Amarin Pharma, INC. | $12.66 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sablaa Ali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.